Guidance

National protocol for COVID-19 Vaccine AstraZeneca (ChAdOx1-S [recombinant])

This protocol is for the administration of COVID-19 Vaccine AstraZeneca (ChAdOx1-S [recombinant]) to individuals in accordance with the national COVID-19 vaccination programme.

From:
UK Health Security Agency
Published
10 January 2021
Last updated
1 April 2022 — See all updates

This publication was withdrawn on

This product is no longer in use in the UK. Please refer to the National protocol for Vaxzevria COVID-19 Vaccine (ChAdOx1-S [recombinant]).

Applies to England

Documents

[Withdrawn] National protocol for COVID-19 Vaccine AstraZeneca (ChAdOx1-S [recombinant]) (v07.00)

Ref: UKHSA gateway number GOV-11819

MS Word Document, 237 KB

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@phe.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

This protocol is for the administration of coronavirus (COVID-19) vaccine AstraZeneca (ChAdOx1-S [recombinant]) by appropriately trained persons.

National protocol for AstraZeneca (ChAdOx1-S [recombinant]) v07.00 is valid from 31 March 2022 to 1 October 2022.

Updates to this page

Published 10 January 2021
Last updated 1 April 2022 + show all updates

  1. Removed expired protocol (v06.00).

  2. Added v07.00 – expiry extension of v06.00.

  3. Added version 6 – see page 4 for change history.

  4. Added version 5 – see page 3 for change history.

  5. Added version 4 - see page 3 for change history.

  6. Added version 3 - see page 3 for change history.

  7. Added version 02.00.

  8. First published.

Sign up for emails or print this page